Emerging Business Models Toward Commercialization of Bioprinting Technology

  • Yakov M. BalakhovskyEmail author
  • Alexander Yu. Ostrovskiy
  • Yusef D. Khesuani
Reference work entry
Part of the Reference Series in Biomedical Engineering book series (RSBE)


After breaking out from the confines of purely academic research, 3D bioprinting technology is quickly developing as a commercial industry and exhibiting the qualities of a mature market with immense potential. We are currently witnessing not only growth in the number of companies and their geographical reach, but also the market’s segmentation. The main models of 3D bioprinting technology commercialization seem to be selling bioprinters and bioinks, services of bioprinting 3D functional tissue constructs – including for drug discovery and disease modeling – selling software, and technological consulting. As the industry advances, so does the legal regulation of the relevant issues. A number of companies are already successfully monetizing the technology and are able to raise financing through various paths. In the near future, we should expect the start of industry consolidation. At this stage of the technology development, rivalries within the industry do not represent a significant threat. The industry is currently characterized by stakeholders joining efforts in order to expedite its advancement and reach the commercial application stage. To accomplish this, the industry must overcome a number of significant hurdles, including achieving the standardization of bioprinting methods, software, and materials.


  1. Antoni D, Burckel H, Josset E, Noel G (2015) Three-dimensional cell culture: a breakthrough in vivo Int. J Mol Sci 16(3):5517–5527CrossRefGoogle Scholar
  2. European Renal Association – European Dialysis and Transplant Association (2016)
  3. Huang G-S, Tseng C-S, Linju YB, Dai L-G, Hsu S-H (2013) Solid freeform-fabricated scaffolds designed to carry multicellular mesenchymal stem cell spheroids. European cells and materials 26:179–194CrossRefPubMedGoogle Scholar
  4. Itoh M, Nakayama K, Morita S (2015) Bio-3D printer undergo Remodeling and endothelialization when implanted in rat aortae. PLoS One 10:1–15Google Scholar
  5. Knowlton S, Onal S, Yu CH, Zhao JJ, Tasoglu S (2015) Bioprinting for cancer research. Trends Biotechnol 33(9):504–513CrossRefGoogle Scholar
  6. Kuo C-Y, Eranki A, Placone JK, Rhodes KR, Aranda-Espinoza H, Fernandes R, Fisher JP, Kim PCW (2016) Development of a 3D printed, bioengineered placenta model to evaluate the role of trophoblast migration in preeclampsia. ACS Biomater Sci Eng 2(10):1817–1826CrossRefGoogle Scholar
  7. Mironov V, Boland T, Trusk T, Forgacs G, Markwald RR (2003) Organ printing: computer-aided jet-based 3D tissue engineering. Trends Biotechnol 21(4):57–61CrossRefGoogle Scholar
  8. Mironov V, Visconti RP, Kasyanov V, Forgacs G, Drake CJ, Markwald RR (2009) Organ printing: tissue spheroids as building blocks. Biomaterials 30(12):2164–2174CrossRefPubMedPubMedCentralGoogle Scholar
  9. Moldovan NI, Hibino N, Nakayama K (2017) Principles of the Kenzan method for robotic cell spheroid-based three-dimensional bioprinting. Tissue Eng Part B Rev 23:237–244CrossRefPubMedGoogle Scholar
  10. Murphy SV, Atala A (2014) 3D bioprinting of tissues and organs. Nat Biotechnol 32(8):773–785CrossRefGoogle Scholar
  11. Nguyen DG, Funk J, Robbins JB, Crogan-Grundy C, Presnell SC, Singer T, Roth AB (2016) Bioprinted 3D primary liver tissues allow assessment of organ-level response to clinical drug induced toxicity in vitro. PLoS One 11(7):e0158674CrossRefPubMedPubMedCentralGoogle Scholar
  12. Ozbolat IT, Peng W, Ozbolat V (2016) Application areas of 3D bioprinting. Drug Discov Today 21(8):1257–1271CrossRefGoogle Scholar
  13. Porter ME (1979) How Competitive Forces Shape Strategy. Harvard Business Review.
  14. Skardal A, Atala A (2015) Biomaterials for integration with 3-D bioprinting. Ann Biomed Eng 43(3):730–746CrossRefGoogle Scholar
  15. Thornton PK (2010) Livestock production: recent trends, future prospects. Philos Trans R Soc Lond Ser B Biol Sci 365(1554):2853–2867CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Yakov M. Balakhovsky
    • 1
    Email author
  • Alexander Yu. Ostrovskiy
    • 2
  • Yusef D. Khesuani
    • 1
    • 3
  1. 1.Vivax Bio, LLCNew YorkUSA
  2. 2.Independent Laboratory INVITROMoscowRussian Federation
  3. 3.The Laboratory of Biotechnical Research 3D Bioprinting SolutionsMoscowRussian Federation

Personalised recommendations